Linezolid, an oxazolidinone-class protein synthesis inhibitor, has been approved since 2000 and is used to treat Gram-positive infections like MRSA. But now, it’s stepping into an entirely new arena: chronic lower back pain.

Why antibiotics?
Emerging research suggests that bacterial infections in herniated disc tissue—think Cutibacterium acnes or coagulase-negative Staphylococcus—is an underlying driver of pain for some patients. The problem? Discs are poorly vascularized, making it difficult for systemic antibiotics to reach therapeutic levels. Past studies with oral amoxicillin alone and in combination with clavulanic acid showed modest pain relief, but directly delivering antibiotics to the infected disc could be a game-changer.

Enter PP353 from Persica Pharmaceuticals
This injectable formulation of linezolid, iohexol (for imaging), and a thermosensitive gel is designed to target degenerate lumbar discs. Once injected, it provides prolonged, high-concentration linezolid exposure at the infection site. Persica’s recent Phase 1b trial results in patients with Modic Type 1 changes (a marker of disc inflammation) are promising—hinting at a future where we treat the root cause of bacterially mediated pain, not just the symptoms. If successful, this approach could also reduce reliance on long-term opioid use.

See Persica’s publications here.

Could this approach transform how we treat chronic back pain worsened by infection?